Clinical Ovarian and Other Gynecologic Cancer最新文献

英文中文

Should Dose-dense Paclitaxel in Combination With Carboplatin Be the New Standard for Treatment for Suboptimally Debulked Patients or Patients Treated With Neoadjuvant Chemotherapy? 剂量密集的紫杉醇联合卡铂是否应该成为治疗亚理想减积患者或接受新辅助化疗患者的新标准?

Clinical Ovarian and Other Gynecologic Cancer

Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2013.12.002

Marilyn Huang, Robert L. Coleman

引用次数: 0

Is There a Role for Bevacizumab in the Primary Treatment of Advanced Ovarian Cancer Off-Protocol? 贝伐单抗在晚期卵巢癌非方案的初级治疗中有作用吗?

Clinical Ovarian and Other Gynecologic Cancer

Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2013.12.003

Jane L. Meisel, Paul Sabbatini

引用次数: 0

Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed With Advanced Ovarian Cancer 早期诊断为晚期卵巢癌的老年患者的化疗模式

Clinical Ovarian and Other Gynecologic Cancer

Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2013.02.001

Scott J. Johnson , Rachael A. Sorg , Rohit D. Borker , Mei Sheng Duh

Background

Over the past decade, chemotherapy treatment for patients with advanced ovarian cancer has expanded, with platinum-based and taxane therapy remaining the backbone. Elderly patients have received little attention, and less is known about the variation and duration of agents elderly women receive for first-line, maintenance, and second-line therapy.

Patients and Methods

Using SEER linked to Medicare claims data, we identified a cohort of women (older than 65 years) with advanced epithelial ovarian cancer who received first-line and/or maintenance therapy between 2003-2009. Over the same period, we identified women who received second-line therapy. We examined the variety of cytotoxic regimens and duration of therapy.

Results

In the patient group, 10,695 patients were eligible for chemotherapy, and 5357 had evidence of receiving any chemotherapy. The first-line sample included 2509 patients, the maintenance sample included 306 patients, and the second-line sample included 1890 patients. Among first-line patients, paclitaxel and carboplatin was the most common regimen. Approximately half of the patients did not successfully complete first-line treatment. Of those eligible for maintenance therapy, about one-quarter of the patients initiated a maintenance regimen, and approximately 10% of those who initiated maintenance therapy completed at least 40 weeks. The most common second-line treatment included platinum-based and taxane therapy, if the patient was platinum-sensitive, or a single-agent anthracycline therapy otherwise.

Conclusion

Additional research should address low first-line treatment completion rates. Most patients eligible for maintenance therapy do not initiate it, and multiple treatment strategies predominate in second-line therapy. There remains a substantial unmet need in therapy options for ovarian cancer.

在过去的十年中，晚期卵巢癌患者的化疗治疗已经扩大，以铂类和紫杉烷类治疗仍然是主要的治疗方法。老年患者很少受到关注，对于老年妇女接受一线、维持和二线治疗的药物的变化和持续时间也知之甚少。患者和方法:使用与医疗保险索赔数据相关的SEER，我们确定了一组在2003-2009年期间接受一线和/或维持治疗的晚期上皮性卵巢癌妇女(65岁以上)。在同一时期，我们确定了接受二线治疗的妇女。我们检查了各种细胞毒性方案和治疗时间。结果患者组符合化疗条件的有10695例，有接受化疗证据的有5357例。一线样本2509例，维持样本306例，二线样本1890例。在一线患者中，紫杉醇加卡铂是最常见的方案。大约一半的患者没有成功完成一线治疗。在符合维持治疗条件的患者中，大约四分之一的患者开始了维持治疗方案，大约10%的开始维持治疗的患者完成了至少40周。如果患者对铂敏感，最常见的二线治疗包括铂基和紫杉烷治疗，否则采用单药蒽环类药物治疗。结论针对一线治疗完成率低的问题需要进一步的研究。大多数符合维持治疗条件的患者不启动它，多种治疗策略在二线治疗中占主导地位。在卵巢癌的治疗选择方面仍有大量未满足的需求。

{"title":"Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed With Advanced Ovarian Cancer","authors":"Scott J. Johnson , Rachael A. Sorg , Rohit D. Borker , Mei Sheng Duh","doi":"10.1016/j.cogc.2013.02.001","DOIUrl":"10.1016/j.cogc.2013.02.001","url":null,"abstract":"<div><h3>Background</h3><p>Over the past decade, chemotherapy treatment for patients with advanced ovarian cancer has expanded, with platinum-based and taxane therapy remaining the backbone. Elderly patients have received little attention, and less is known about the variation and duration of agents elderly women receive for first-line, maintenance, and second-line therapy.</p></div><div><h3>Patients and Methods</h3><p>Using SEER linked to Medicare claims data, we identified a cohort of women (older than 65 years) with advanced epithelial ovarian cancer who received first-line and/or maintenance therapy between 2003-2009. Over the same period, we identified women who received second-line therapy. We examined the variety of cytotoxic regimens and duration of therapy.</p></div><div><h3>Results</h3><p>In the patient group, 10,695 patients were eligible for chemotherapy, and 5357 had evidence of receiving any chemotherapy. The first-line sample included 2509 patients, the maintenance sample included 306 patients, and the second-line sample included 1890 patients. Among first-line patients, paclitaxel and carboplatin was the most common regimen. Approximately half of the patients did not successfully complete first-line treatment. Of those eligible for maintenance therapy, about one-quarter of the patients initiated a maintenance regimen, and approximately 10% of those who initiated maintenance therapy completed at least 40 weeks. The most common second-line treatment included platinum-based and taxane therapy, if the patient was platinum-sensitive, or a single-agent anthracycline therapy otherwise.</p></div><div><h3>Conclusion</h3><p>Additional research should address low first-line treatment completion rates. Most patients eligible for maintenance therapy do not initiate it, and multiple treatment strategies predominate in second-line therapy. There remains a substantial unmet need in therapy options for ovarian cancer.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"5 2","pages":"Pages 67-77.e1"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2013.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78915778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Role of Anti-Müllerian Hormone in Diagnosing Granulosa Cell Tumor: A Case Report 抗<s:1>勒氏激素在颗粒细胞瘤诊断中的作用1例报告

Clinical Ovarian and Other Gynecologic Cancer

Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2012.12.001

Aarti Umranikar , Mili Saran , Nick Brook , Neeta Singh , Darren Fowler , Ying Cheong

引用次数: 1

Immune Surveillance Tissue Antigen Profiling in Advanced Ovarian Cancer 晚期卵巢癌的免疫监测组织抗原谱分析

Clinical Ovarian and Other Gynecologic Cancer

Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2012.09.001

Patrick J. Stiff , Ronald K. Potkul , Girish Venkataraman , Payal Sojitra , Maureen L. Drakes

Aim

A knowledge of tumor-related antigens associated with survival of patients with ovarian cancer could contribute toward the development of tests for early diagnosis and could provide targets for the design of novel immunotherapy for advanced ovarian cancer. We conducted a pilot immunohistochemical study to determine a group of antigens in ovarian tumor masses that correlate with survival.

Methods

We studied T-cell subsets and tumor antigens on 69 cases of paraffin-embedded patient blocks to determine if any correlated with survival in this disease. These were identified by staining for CD3, CD8, FoxP3, New York esophageal-1 (NY-ESO-1), melanoma-associated antigen (MAGE) A, cyclin E, and intercellular adhesion molecule-1 (ICAM-1) antigens in tissue when using specific antibodies.

Results

Study patients had a median age of 58 years and an overall survival of 31%. Infiltrating CD3⁺ T cells correlated with improved survival of patients (P = .002, log-rank test). The frequency of cyclin E, ICAM-1, CD8, and FoxP3 expressing cells were not statistically associated with survival. MAGE-A was expressed in 10 (45%) of 22 whole-tissue sections studied, and this expression correlated with decreased survival (P = .03, log-rank test). The presence and frequency of FoxP3 infiltrating suppressor T cells was associated with high-stage disease (P = .02, χ² test; P = .03, Wilcoxon test).

Conclusions

The significance of CD3 T cells in tumor tissue may be primarily associated with an active antitumor immune response. MAGE-A family members may represent successful antigens for immunotherapeutic targeting in ovarian cancer.

了解与卵巢癌患者生存相关的肿瘤相关抗原有助于开发早期诊断测试，并可为设计晚期卵巢癌的新型免疫疗法提供靶点。我们进行了一项试点免疫组织化学研究，以确定卵巢肿瘤肿块中与生存相关的一组抗原。方法对69例石蜡包埋患者块的t细胞亚群和肿瘤抗原进行研究，以确定它们是否与该疾病的生存相关。当使用特异性抗体时，通过对组织中的CD3、CD8、FoxP3、New York esophageal-1 (NY-ESO-1)、黑色素瘤相关抗原(MAGE) A、细胞周期蛋白E和细胞间粘附分子-1 (ICAM-1)抗原进行染色鉴定。研究患者的中位年龄为58岁，总生存率为31%。浸润CD3+ T细胞与患者生存率提高相关(P = 0.002, log-rank检验)。cyclin E、ICAM-1、CD8和FoxP3表达细胞的频率与生存率无统计学相关性。研究的22个全组织切片中有10个(45%)表达MAGE-A，其表达与生存率降低相关(P = 0.03, log-rank检验)。FoxP3浸润抑制性T细胞的存在和频率与高分期疾病相关(P = 0.02， χ2检验;P = .03, Wilcoxon检验)。结论cd3t细胞在肿瘤组织中的作用可能主要与肿瘤免疫反应有关。MAGE-A家族成员可能代表卵巢癌免疫治疗靶向的成功抗原。

{"title":"Immune Surveillance Tissue Antigen Profiling in Advanced Ovarian Cancer","authors":"Patrick J. Stiff , Ronald K. Potkul , Girish Venkataraman , Payal Sojitra , Maureen L. Drakes","doi":"10.1016/j.cogc.2012.09.001","DOIUrl":"10.1016/j.cogc.2012.09.001","url":null,"abstract":"<div><h3>Aim</h3><p>A knowledge of tumor-related antigens associated with survival of patients with ovarian cancer could contribute toward the development of tests for early diagnosis and could provide targets for the design of novel immunotherapy for advanced ovarian cancer. We conducted a pilot immunohistochemical study to determine a group of antigens in ovarian tumor masses that correlate with survival.</p></div><div><h3>Methods</h3><p>We studied T-cell subsets and tumor antigens on 69 cases of paraffin-embedded patient blocks to determine if any correlated with survival in this disease. These were identified by staining for CD3, CD8, FoxP3, New York esophageal-1 (NY-ESO-1), melanoma-associated antigen (MAGE) A, cyclin E, and intercellular adhesion molecule-1 (ICAM-1) antigens in tissue when using specific antibodies.</p></div><div><h3>Results</h3><p>Study patients had a median age of 58 years and an overall survival of 31%. Infiltrating CD3<sup>+</sup> T cells correlated with improved survival of patients (<em>P</em> = .002, log-rank test). The frequency of cyclin E, ICAM-1, CD8, and FoxP3 expressing cells were not statistically associated with survival. MAGE-A was expressed in 10 (45%) of 22 whole-tissue sections studied, and this expression correlated with decreased survival (<em>P</em> = .03, log-rank test). The presence and frequency of FoxP3 infiltrating suppressor T cells was associated with high-stage disease (<em>P</em> = .02, χ<sup>2</sup> test; <em>P</em> = .03, Wilcoxon test).</p></div><div><h3>Conclusions</h3><p>The significance of CD3 T cells in tumor tissue may be primarily associated with an active antitumor immune response. MAGE-A family members may represent successful antigens for immunotherapeutic targeting in ovarian cancer.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"5 2","pages":"Pages 78-86"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2012.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77518395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Paraneoplastic Anti-N-Methyl-D-Apartate-Receptor Encephalitis Associated With an Immature Teratoma 与未成熟畸胎瘤相关的副肿瘤抗n -甲基- d -分离物受体脑炎

Clinical Ovarian and Other Gynecologic Cancer

Pub Date : 2012-12-01 DOI: 10.1016/j.cogc.2013.02.002

A. Mitch Dizon , Karen L. Samples , Kristopher J. Kimball , Larry C. Kilgore

引用次数: 1

Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer 卵巢癌患者血小板衍生生长因子基因多态性

Clinical Ovarian and Other Gynecologic Cancer

Pub Date : 2012-06-01 DOI: 10.1016/j.cloc.2012.02.020

Christine Vestergaard Madsen , Karina Dahl Steffensen , Marianne Waldstrøm , Rikke Fredslund Andersen , Charlotte Hasselholt Søgaard , Ivan Brandslund , Anders Jakobsen

Introduction

New reliable and validated markers are desirable in the treatment of ovarian cancer. The platelet-derived growth factor (PDGF) system plays an important role in tumor growth and angiogenesis, and high expression of PDGF/PDGF receptor (PDGFR) has been reported in ovarian cancer. Single nucleotide polymorphisms (SNPs) within a gene may be important for the function of the protein. This had led to the hypothesis that SNPs within the PDGF system could have clinical relevance as prognostic biomarkers in ovarian cancer.

Methods

The study included hypothesis-generating patient material from 170 patients with histologically verified epithelial ovarian cancer in which 5 tagging SNPs in the promoter region of the PDGF-AA, PDGF-BB, PDGFR-α, and PDGFR-β genes were analyzed by means of SNaPshot Multiplex (Applied Biosystems, Carlsbad, CA) and sequencing methods. The results were validated in an independent second cohort of 85 patients.

Results

In the hypothesis-generating study, survival analyses were made for all 5 SNPs. PDGF-AA 1589 G/T genotype was found to be associated with overall survival in univariate analysis (P = .03), with a clear trend seen in Cox multivariate analysis (P = .12; hazard ratio, 0.75). However, the suggested prognostic importance of PDGF-AA 1589 G/T was not confirmed in the second cohort.

Conclusion

Tagging SNPs in the promoter region of the PDGF-AA, PDGF-BB, PDGFR-α, and PDGFR-β genes, as evaluated here, are not likely to be of prognostic importance in patients with ovarian cancer.

新的可靠和有效的标志物是卵巢癌治疗中需要的。血小板衍生生长因子(PDGF)系统在肿瘤生长和血管生成中起重要作用，PDGF/PDGF受体(PDGFR)在卵巢癌中高表达已被报道。基因内的单核苷酸多态性(SNPs)可能对蛋白质的功能很重要。这导致了PDGF系统内的snp可能作为卵巢癌预后生物标志物具有临床相关性的假设。方法采用SNaPshot Multiplex (Applied Biosystems, Carlsbad, CA)和测序方法，对来自170例组织学证实的上皮性卵巢癌患者的假设生成患者材料进行分析，其中PDGF-AA、PDGF-BB、PDGFR-α和PDGFR-β基因启动子区域的5个标记snp进行分析。结果在独立的第二队列85例患者中得到验证。结果在产生假设的研究中，对所有5个snp进行了生存分析。单因素分析发现PDGF-AA 1589 G/T基因型与总生存率相关(P = .03)， Cox多因素分析发现PDGF-AA 1589 G/T基因型与总生存率相关(P = .12;风险比，0.75)。然而，PDGF-AA 1589 G/T的预后重要性在第二队列中未得到证实。结论标记PDGF-AA、PDGF-BB、PDGFR-α和PDGFR-β基因启动子区域的snp对卵巢癌患者的预后不太可能具有重要意义。

{"title":"Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer","authors":"Christine Vestergaard Madsen , Karina Dahl Steffensen , Marianne Waldstrøm , Rikke Fredslund Andersen , Charlotte Hasselholt Søgaard , Ivan Brandslund , Anders Jakobsen","doi":"10.1016/j.cloc.2012.02.020","DOIUrl":"10.1016/j.cloc.2012.02.020","url":null,"abstract":"<div><h3>Introduction</h3><p>New reliable and validated markers are desirable in the treatment of ovarian cancer. The platelet-derived growth factor (PDGF) system plays an important role in tumor growth and angiogenesis, and high expression of PDGF/PDGF receptor (PDGFR) has been reported in ovarian cancer. Single nucleotide polymorphisms (SNPs) within a gene may be important for the function of the protein. This had led to the hypothesis that SNPs within the PDGF system could have clinical relevance as prognostic biomarkers in ovarian cancer.</p></div><div><h3>Methods</h3><p>The study included hypothesis-generating patient material from 170 patients with histologically verified epithelial ovarian cancer in which 5 tagging SNPs in the promoter region of the <em>PDGF-AA</em>, <em>PDGF-BB, PDGFR-α,</em> and <em>PDGFR-β</em> genes were analyzed by means of SNaPshot Multiplex (Applied Biosystems, Carlsbad, CA) and sequencing methods. The results were validated in an independent second cohort of 85 patients.</p></div><div><h3>Results</h3><p>In the hypothesis-generating study, survival analyses were made for all 5 SNPs. <em>PDGF-AA 1589 G/T</em> genotype was found to be associated with overall survival in univariate analysis (<em>P</em> = .03), with a clear trend seen in Cox multivariate analysis (<em>P</em> = .12; hazard ratio, 0.75). However, the suggested prognostic importance of <em>PDGF-AA 1589 G/T</em> was not confirmed in the second cohort.</p></div><div><h3>Conclusion</h3><p>Tagging SNPs in the promoter region of the <em>PDGF-AA, PDGF-BB, PDGFR-α</em>, and <em>PDGFR-β</em> genes, as evaluated here, are not likely to be of prognostic importance in patients with ovarian cancer.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"5 1","pages":"Pages 10-16"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cloc.2012.02.020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80302009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Unusual Collision Tumor of Ovary: Endometrioid Adenocarcinoma and Teratoma 卵巢异常碰撞瘤:子宫内膜样腺癌和畸胎瘤

Clinical Ovarian and Other Gynecologic Cancer

Pub Date : 2012-06-01 DOI: 10.1016/j.cloc.2011.12.001

Eliyaz Ahmed, Shatrughan P. Sah, Anilkumar Adikesavalu, Krishnaswamy Madhavan, Khalil Razvi

引用次数: 5

Ovarian Endometrioid Adenocarcinoma With a Yolk Sac Tumor Component in a Postmenopausal Woman: Case Report and Review of the Literature 绝经后妇女卵巢子宫内膜样腺癌伴卵黄囊肿瘤成分:病例报告及文献回顾

Clinical Ovarian and Other Gynecologic Cancer

Pub Date : 2012-06-01 DOI: 10.1016/j.cogc.2012.05.003

Jacopo Giuliani , Marina Marzola , Pamela Pizzutilo , Ruby Martinello , Andrea Marzola , Monica Indelli , Antonio Frassoldati

引用次数: 6

A New Era for Clinical Ovarian and Other Gynecologic Cancer 临床卵巢癌和其他妇科肿瘤的新时代

Clinical Ovarian and Other Gynecologic Cancer

Pub Date : 2012-06-01 DOI: 10.1016/j.cogc.2012.06.002

Ronald D. Alvarez (Editor-in-Chief)

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Clinical Ovarian and Other Gynecologic Cancer

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀